• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

AMCP CEO Susan Cantrell Addresses Complex Causes of High Drug Prices and Advocates for Multi-Stakeholder Solutions in US Healthcare


In this first part of a video series, Susan Cantrell, CEO of AMCP, discussed root causes of high drug prices, its impact on underserved communities and Medicare price negotiation, emphasizing AMCP's actions and the role of decreasing drug prices for equity.

AMCP CEO Susan Cantrell spoke with Managed Healthcare Executive about the challenges of pinpointing specific causes for high drug prices.

Cantrell emphasized the crucial role of innovation in driving prescription drug costs, sharing the exciting advancements in therapies for long-standing health issues. However, she did caution against some policy solutions that might intervene in any innovations.

Additionally, she stressed the importance of payment models, supporting the Medicaid Value-Based Payments for Patients (MVP) Act to enhance Medicaid patients' access to high-cost therapies.

At AMCP, her team focuses on advocating for the appropriate use of medications and promoting generics and biosimilars to address cost concerns.

When asked about the significant increase in existing prescription drug costs, Cantrell acknowledged the steady rise but stressed the complexity of data and sources in providing precise figures.

Lastly, Cantrell highlighted the need for a multi-stakeholder approach involving patients, health plans, benefit managers, employers, manufacturers and healthcare delivery systems to find effective solutions that balance access, affordability and innovation.

Related Content
© 2024 MJH Life Sciences

All rights reserved.